CN Patent

CN111377935B — 选择性cdk4/6抑制剂及其应用

Assigned to Wuhan Guanggu Generic Pharmaceutical Research Institute Co ltd · Expires 2021-06-29 · 5y expired

What this patent protects

本发明公开了一种选择性CDK4/6抑制剂及其应用。该化合物为如式Ia所示的化合物、其药学上可接受的盐、水合物、溶剂化物、代谢产物、立体异构体、互变异构体或前药。该化合物能够用于制备成治疗和/或预防癌症的药物。

USPTO Abstract

本发明公开了一种选择性CDK4/6抑制剂及其应用。该化合物为如式Ia所示的化合物、其药学上可接受的盐、水合物、溶剂化物、代谢产物、立体异构体、互变异构体或前药。该化合物能够用于制备成治疗和/或预防癌症的药物。

Drugs covered by this patent

trilaciclib-dihydrochloride (TRILACICLIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN111377935B
Jurisdiction: CN
Classification: —
Expires: 2021-06-29
Drug substance claim: No
Drug product claim: No
Assignee: Wuhan Guanggu Generic Pharmaceutical Research Institute Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.